A Novel Intervention Including Individualized Nutritional Recommendations Reduces Hemoglobin A1c Level, Medication Use, and Weight in Type 2 Diabetes.

Autor: McKenzie AL; Virta Health, San Francisco, CA, United States., Hallberg SJ; Virta Health, San Francisco, CA, United States.; Indiana University Health Arnett, Medically Supervised Weight Loss, Lafayette, IN, United States., Creighton BC; Virta Health, San Francisco, CA, United States., Volk BM; Virta Health, San Francisco, CA, United States., Link TM; Virta Health, San Francisco, CA, United States., Abner MK; Virta Health, San Francisco, CA, United States., Glon RM; Virta Health, San Francisco, CA, United States., McCarter JP; Virta Health, San Francisco, CA, United States., Volek JS; Virta Health, San Francisco, CA, United States., Phinney SD; Virta Health, San Francisco, CA, United States.
Jazyk: angličtina
Zdroj: JMIR diabetes [JMIR Diabetes] 2017 Mar 07; Vol. 2 (1), pp. e5. Date of Electronic Publication: 2017 Mar 07.
DOI: 10.2196/diabetes.6981
Abstrakt: Background: Type 2 diabetes (T2D) is typically managed with a reduced fat diet plus glucose-lowering medications, the latter often promoting weight gain.
Objective: We evaluated whether individuals with T2D could be taught by either on-site group or remote means to sustain adequate carbohydrate restriction to achieve nutritional ketosis as part of a comprehensive intervention, thereby improving glycemic control, decreasing medication use, and allowing clinically relevant weight loss.
Methods: This study was a nonrandomized, parallel arm, outpatient intervention. Adults with T2D (N=262; mean age 54, SD 8, years; mean body mass index 41, SD 8, kg·m -2 ; 66.8% (175/262) women) were enrolled in an outpatient protocol providing intensive nutrition and behavioral counseling, digital coaching and education platform, and physician-guided medication management. A total of 238 participants completed the first 10 weeks. Body weight, capillary blood glucose, and beta-hydroxybutyrate (BOHB) levels were recorded daily using a mobile interface. Hemoglobin A 1c (HbA 1c ) and related biomarkers of T2D were evaluated at baseline and 10-week follow-up.
Results: Baseline HbA 1c level was 7.6% (SD 1.5%) and only 52/262 (19.8%) participants had an HbA 1c level of <6.5%. After 10 weeks, HbA 1c level was reduced by 1.0% (SD 1.1%; 95% CI 0.9% to 1.1%, P<.001), and the percentage of individuals with an HbA 1c level of <6.5% increased to 56.1% (147/262). The majority of participants (234/262, 89.3%) were taking at least one diabetes medication at baseline. By 10 weeks, 133/234 (56.8%) individuals had one or more diabetes medications reduced or eliminated. At follow-up, 47.7% of participants (125/262) achieved an HbA 1c level of <6.5% while taking metformin only (n=86) or no diabetes medications (n=39). Mean body mass reduction was 7.2% (SD 3.7%; 95% CI 5.8% to 7.7%, P<.001) from baseline (117, SD 26, kg). Mean BOHB over 10 weeks was 0.6 (SD 0.6) mmol·L -1 indicating consistent carbohydrate restriction. Post hoc comparison of the remote versus on-site means of education revealed no effect of delivery method on change in HbA 1c (F 1,260 =1.503, P=.22).
Conclusions: These initial results indicate that an individualized program delivered and supported remotely that incorporates nutritional ketosis can be highly effective in improving glycemic control and weight loss in adults with T2D while significantly decreasing medication use.
(©Amy L McKenzie, Sarah J Hallberg, Brent C Creighton, Brittanie M Volk, Theresa M Link, Marcy K Abner, Roberta M Glon, James P McCarter, Jeff S Volek, Stephen D Phinney. Originally published in JMIR Diabetes (http://diabetes.jmir.org), 07.03.2017.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje